INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
GR
Corporate insider

Gray Nancy Ryan

DirectorCIK 0001714949

EDGAR filingsOpen in network
Disclosed transactions8
Buys / sells0 / 2
Max Insider Score51
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Grant or award
A—
836 sh
Jun 5, 2026Jun 9, 2026
traded Jun 5, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    LIGAND PHARMACEUTICALS INCDirector · Nov 12, 2025
5
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Grant or award
A
—
2,938 sh
Jun 5, 2026
Jun 9, 2026
traded Jun 5, 2026
+4d
SEC FORM 4

Evidence

51
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$619K
3,015 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

26
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M$235K
3,556 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

15
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M—
3,015 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

51
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$731K
3,556 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

26
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M$222K
3,015 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

15
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M—
3,556 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence